🟢 Corcept Therapeutics is trading 6.19% up in pre-market after Q3 revenue surged 64% year over year

Corcept Therapeutics is trading at $87.00, up 6.19% in pre-market after reporting third-quarter revenue of $340.5 million, up 64% year over year.

• Lifyorli generated $91.4 million, up 92% from the prior quarter; Korlym and its authorized generic contributed $249.1 million.
• Management reiterated 2026 revenue guidance of $1.1–$1.2 billion.
• Released after the close November 3, results were the clearest company-specific catalyst for the November 4 pre-market alert.